A phase 0 single dose study to evaluate the pharmacokinetics/-dynamics and specific targeting properties of 124-I-F8IL10 in patients with active rheumatoid arthritis.
Phase of Trial: Phase 0
Latest Information Update: 22 May 2013
At a glance
- Drugs F8 IL10 (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- 21 May 2013 New trial record